Literature DB >> 10694485

Molecular cloning and genomic structure of the betaTRCP2 gene on chromosome 5q35.1.

J Koike1, N Sagara, H Kirikoshi, A Takagi, T Miwa, M Hirai, M Katoh.   

Abstract

Beta-catenin, IkappaBalpha, and HIV Vpu are recruited to the ubiquitin-proteasome degradation pathway by betaTRCP, one of the components of the ubiquitin ligase complex. betaTRCP2, a related gene of betaTRCP, was cloned and characterized. Three isoforms, betaTRCP2A, betaTRCP2B, and betaTRCP2C, were identified. All of these betaTRCP2 isoforms consist of an F-box and seven WD repeats. Human betaTRCP2A shows 86% total amino acid identity with human betaTRCP. betaTRCP2 mRNA of 4.5 kb in size was detected almost ubiquitously. Sequence analyses on betaTRCP2 genomic clones revealed that the betaTRCP2 gene consists of at least 14 exons. Exons 1 and 4-14 are shared among all betaTRCP2 isoforms. betaTRCP2A of 508 amino acids lacks exons 2 and 3, betaTRCP2B of 529 amino acids contains exon 3, and betaTRCP2C of 542 amino acids contains exon 2. These results indicate that three betaTRCP2 isoforms are transcribed due to alternative splicing. The betaTRCP2 gene has been mapped to human chromosome 5q35.1 by fluorescence in situ hybridization. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10694485     DOI: 10.1006/bbrc.2000.2241

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Silencing of both beta-TrCP1 and HOS (beta-TrCP2) is required to suppress human immunodeficiency virus type 1 Vpu-mediated CD4 down-modulation.

Authors:  Christophe Butticaz; Olivier Michielin; Josiane Wyniger; Amalio Telenti; Sylvia Rothenberger
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

2.  HIV-1 Vpu Downmodulates ICAM-1 Expression, Resulting in Decreased Killing of Infected CD4+ T Cells by NK Cells.

Authors:  Scott M Sugden; Tram N Q Pham; Éric A Cohen
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

3.  β-transducin repeat-containing E3 ubiquitin protein ligase inhibits migration, invasion and proliferation of glioma cells.

Authors:  Jun Liang; Wei-Feng Wang; Shao Xie; Xian-Li Zhang; Wei-Feng Qi; Xiu-Ping Zhou; Jin-Xia Hu; Qiong Shi; Ru-Tong Yu
Journal:  Oncol Lett       Date:  2017-07-07       Impact factor: 2.967

4.  Interaction and co-localization of JC virus large T antigen and the F-box protein β-transducin-repeat containing protein.

Authors:  Marta M Reviriego-Mendoza; Richard J Frisque
Journal:  Virology       Date:  2010-11-23       Impact factor: 3.616

Review 5.  The ubiquitin-proteasome system meets angiogenesis.

Authors:  Nader Rahimi
Journal:  Mol Cancer Ther       Date:  2012-02-21       Impact factor: 6.261

6.  Fbxw11 impairs the repopulation capacity of hematopoietic stem/progenitor cells.

Authors:  Lina Wang; Yongjun Piao; Dongyue Zhang; Wenli Feng; Chenchen Wang; Xiaoxi Cui; Qian Ren; Xiaofan Zhu; Guoguang Zheng
Journal:  Stem Cell Res Ther       Date:  2022-06-11       Impact factor: 8.079

Review 7.  Role of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases in skin cancer.

Authors:  Chuan-Ming Xie; Wenyi Wei; Yi Sun
Journal:  J Genet Genomics       Date:  2013-02-10       Impact factor: 4.275

8.  Multiple isoforms of beta-TrCP display differential activities in the regulation of Wnt signaling.

Authors:  Eunjeong Seo; Hyunjoon Kim; Rokki Kim; Sangmoon Yun; Minseong Kim; Jin-Kwan Han; Frank Costantini; Eek-Hoon Jho
Journal:  Cell Signal       Date:  2008-09-25       Impact factor: 4.315

Review 9.  Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis.

Authors:  Masaru Katoh
Journal:  Stem Cell Rev       Date:  2007-01       Impact factor: 6.692

10.  Fbxw11 promotes the proliferation of lymphocytic leukemia cells through the concomitant activation of NF-κB and β-catenin/TCF signaling pathways.

Authors:  Lina Wang; Wenli Feng; Xiao Yang; Feifei Yang; Rong Wang; Qian Ren; Xiaofan Zhu; Guoguang Zheng
Journal:  Cell Death Dis       Date:  2018-04-01       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.